Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS-02: Liposomal Irinotecan-based Regimens in Second-Line Metastatic Colorectal Cancer
NCT07585279Phase 3Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- May 2026
- Primary completion
- Feb 2031
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nanoliposomal irinotecan in metastatic colorectal cancer (mCRC), sponsored by The Fourth Hospital of Hebei Medical University. Planned start May 2026; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07585279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07585279.